Annexin Pharmaceuticals AB (ANNX) Completes Phase 2a NEXUS Enrollment

Annexin Pharmaceuticals AB (ANNX) has finished enrolling 12 patients in its Phase 2a NEXUS study of vanexin. The company expects topline data by the end of Q1 2027, according to the press release.

Original reporting
Published Oct 22, 2026, 6:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 6:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Annexin Pharmaceuticals AB (ANNX) Completes Phase 2a NEXUS Enrollment — source image
Decision brief

The 30-second read

$ANNXNeutralMed
01

Why it matters

The enrollment completion is a concrete operational milestone that reduces execution risk and sets a clear timeline for data release, which markets will price in.

02

Market read

First‑report trial enrollment news; modest but actionable for biotech‑focused traders awaiting data.

03

What to watch

Potential delays in data readout or regulatory feedback could mute the expected upside.

Relevance 7/10Novelty 8/10Timing: today

Background

Annexin Pharmaceuticals AB is a clinical‑stage biotech developing vanexin for an undisclosed indication. The NEXUS Phase 2a study is a key step toward later‑stage trials.

Company-level read

Ticker impact

$ANNXNeutralHigh confidence
Context

Annexin Pharmaceuticals completed enrollment of all 12 patients in its Phase 2a NEXUS study, a first‑report disclosure of trial progress.

Expected impact

potential upside as investors price in the upcoming data readout

Evidence & confidence

The news is a primary corporate event; no new data yet, but the removal of a trial‑execution risk typically supports a modest bullish bias.

Market effects

Adds a positive catalyst to the biotech sector, where trial milestones often move peer stocks.

Limited to investors tracking European and US biotech pipelines.

Minor; primarily relevant to specialty biotech investors.

Counterpoint

If the upcoming data disappoint, the stock could face a sharp sell‑off despite the enrollment news.

Key entities

  • Annexin Pharmaceuticals AB

    Clinical‑stage biotech firm conducting the NEXUS trial.

Related articles

$ANNXHigh

Wells Fargo Names Top Pick in Biotechnology Sector

Wells Fargo named Annexon, Inc. its top biotech pick, maintaining an Overweight rating and $27.00 price target. The firm cited the company's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA) as a key catalyst, with a 55% success probability. Annexon has near-term catalysts, including a Q4 2026 data readout and a BLA submission. The company has $213M in cash and a $200M credit facility. Shares are down 16% YTD, underperforming the SPDR S&P Biotech ETF's 29% gain.

$ANNXMed

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (ANNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in G

$ANNXMed

H.C. Wainwright raises Annexon stock price target on GBS approval prospects

H.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.

$ANNXMed

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.

$ANNXMedAI 8/10

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.